Xiaoli Chai

888 total citations · 1 hit paper
12 papers, 599 citations indexed

About

Xiaoli Chai is a scholar working on Oncology, Hepatology and Molecular Biology. According to data from OpenAlex, Xiaoli Chai has authored 12 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Hepatology and 3 papers in Molecular Biology. Recurrent topics in Xiaoli Chai's work include Cancer Immunotherapy and Biomarkers (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Parasitic infections in humans and animals (3 papers). Xiaoli Chai is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Parasitic infections in humans and animals (3 papers). Xiaoli Chai collaborates with scholars based in China. Xiaoli Chai's co-authors include Jianjun Zou, Linna Wang, Zhenggang Ren, Xiaohong Chen, Yuxian Bai, Shukui Qin, Jianping Xiong, Weijia Fang, Enxiao Li and Xiaoyan Lin and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Journal of Hematology & Oncology.

In The Last Decade

Xiaoli Chai

10 papers receiving 595 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

2020 418 citations Shukui Qin, Zhenggang Ren et al. The Lancet Oncology profile →

Peers

Xiaoli Chai

ONCOL

HEPAT

PFM

PRM

SURGE

Birgit Grünberger Austria

Robert Hüneburg Germany

Wai‐Key Yuen Hong Kong

Howard M. Karpoff United States

Jiewen Peng China

A. Wein Germany

Hubert Darius J. Daniel India

Young Hwa Chung South Korea

Yufu Ye China

Tse‐Ching Chen Taiwan

Birgit Grünberger Austria

Xiaoli Chai

153 ×0.4

ONCOL

226 ×0.7

HEPAT

191 ×1.2

PFM

126 ×0.8

PRM

172 ×1.5

SURGE

Citations per year, relative to Xiaoli Chai Xiaoli Chai (= 1×) peers Birgit Grünberger

Countries citing papers authored by Xiaoli Chai

Since Specialization

Citations

This map shows the geographic impact of Xiaoli Chai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoli Chai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoli Chai more than expected).

Fields of papers citing papers by Xiaoli Chai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoli Chai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoli Chai. The network helps show where Xiaoli Chai may publish in the future.

Co-authorship network of co-authors of Xiaoli Chai

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoli Chai. A scholar is included among the top collaborators of Xiaoli Chai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoli Chai. Xiaoli Chai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Wang, Qiming, Xiaoli Chai, Rongbo Lin, et al.. (2025). A phase 1 dose escalation and expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.. Journal of Clinical Oncology. 43(16_suppl). 8089–8089.

2.

Qin, Shukui, Ying Cheng, Qiming Wang, et al.. (2024). Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2611–2611.

3.

Sun, Yan, Xiaoli Chai, Zhen Wang, et al.. (2024). First-in-human study of ZG0895, a TLR8 selective agonist, as monotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15103–e15103. 1 indexed citations

4.

Qin, Shukui, Ying Cheng, Lihua Wu, et al.. (2023). First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e14504–e14504. 1 indexed citations

5.

Liu, Rongrui, Xiujuan Qu, Nong Yang, Xiaoli Chai, & Jianming Xu. (2023). First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e15127–e15127. 7 indexed citations

6.

Ren, Zhenggang, Shukui Qin, Zhiqiang Meng, et al.. (2021). A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer. 10(5). 500–509. 16 indexed citations

7.

Qin, Shukui, Zhenggang Ren, Zhiqiang Meng, et al.. (2020). Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. The Lancet Oncology. 21(4). 571–580. 418 indexed citations breakdown →

8.

Wang, Feng, Shukui Qin, Xinchen Sun, et al.. (2020). Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. Journal of Hematology & Oncology. 13(1). 97 indexed citations

9.

Cheng, Zhe, et al.. (2019). Impairing the maintenance of germinative cells in Echinococcus multilocularis by targeting Aurora kinase. PLoS neglected tropical diseases. 13(5). e0007425–e0007425. 4 indexed citations

10.

Cheng, Zhe, et al.. (2017). Identification of EmSOX2, a member of the Sox family of transcription factors, as a potential regulator of Echinococcus multilocularis germinative cells. International Journal for Parasitology. 47(10-11). 625–632. 7 indexed citations

11.

Cheng, Zhe, Fan Liu, Xiu Li, et al.. (2017). EGF-mediated EGFR/ERK signaling pathway promotes germinative cell proliferation in Echinococcus multilocularis that contributes to larval growth and development. PLoS neglected tropical diseases. 11(2). e0005418–e0005418. 40 indexed citations

12.

Bi, Feng, Meng Qiu, Xiaoli Chai, et al.. (2017). A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 35(15_suppl). e15682–e15682. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact